



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | |
|---|-----------|---|
| (51) International Patent Classification ⁶ : A61K 38/20, 47/00, 47/26 | A1 | (11) International Publication Number: WO 96/24369 (43) International Publication Date: 15 August 1996 (15.08.96) |
| <p>(21) International Application Number: PCT/US96/01382</p> <p>(22) International Filing Date: 2 February 1996 (02.02.96)</p> <p>(30) Priority Data: 08/384,062 6 February 1995 (06.02.95) US</p> <p>(71) Applicant: GENETICS INSTITUTE, INC. [US/US]; 87 CambridgePark Drive, Cambridge, MA 02140 (US).</p> <p>(72) Inventors: WARNE, Nicholas, W.; 120 Tyler Street, Methuen, MA 01844 (US). CROWLEY, Thomas, J.; 194 Sylvan Street, Malden, MA 02148 (US). SMITH, Tracy, M.; 25 Logan Street #2L, Lawrence, MA 01841 (US).</p> <p>(74) Agent: BROWN, Scott, A.; Genetics Institute, Inc., 87 CambridgePark Drive, Cambridge, MA 02140 (US).</p> | | <p>(81) Designated States: AU, CA, JP, MX, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p> |
| <p>(54) Title: FORMULATIONS FOR IL-12</p> <p>(57) Abstract</p> <p>Provided by the present invention are novel compositions and methods for obtaining concentrated preparations of IL-12 and formulations of IL-12 suitable for storage and administration.</p> | | |

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | |
|----|--------------------------|----|--|----|--------------------------|
| AM | Armenia | GB | United Kingdom | MW | Malawi |
| AT | Austria | GE | Georgia | MX | Mexico |
| AU | Australia | GN | Guinea | NE | Niger |
| BB | Barbados | GR | Greece | NL | Netherlands |
| BE | Belgium | HU | Hungary | NO | Norway |
| BF | Burkina Faso | IE | Ireland | NZ | New Zealand |
| BG | Bulgaria | IT | Italy | PL | Poland |
| BJ | Benin | JP | Japan | PT | Portugal |
| BR | Brazil | KE | Kenya | RO | Romania |
| BY | Belarus | KG | Kyrgyzstan | RU | Russian Federation |
| CA | Canada | KP | Democratic People's Republic of Korea | SD | Sudan |
| CF | Central African Republic | KR | Republic of Korea | SE | Sweden |
| CG | Congo | KZ | Kazakhstan | SG | Singapore |
| CH | Switzerland | LI | Liechtenstein | SI | Slovenia |
| CI | Côte d'Ivoire | LK | Sri Lanka | SK | Slovakia |
| CM | Cameroon | LR | Liberia | SN | Senegal |
| CN | China | LT | Lithuania | SZ | Swaziland |
| CS | Czechoslovakia | LU | Luxembourg | TD | Chad |
| CZ | Czech Republic | LV | Latvia | TG | Togo |
| DE | Germany | MC | Monaco | TJ | Tajikistan |
| DK | Denmark | MD | Republic of Moldova | TT | Trinidad and Tobago |
| EE | Estonia | MG | Madagascar | UA | Ukraine |
| ES | Spain | ML | Mali | UG | Uganda |
| FI | Finland | MN | Mongolia | US | United States of America |
| FR | France | MR | Mauritania | UZ | Uzbekistan |
| GA | Gabon | | | VN | Viet Nam |

5

FORMULATIONS FOR IL-12**FIELD OF INVENTION**

The present invention relates generally to novel formulations comprising interleukin-12 ("IL-12").

10

BACKGROUND OF THE INVENTION

IL-12 is a heterodimeric cytokine (comprising an approximately 35 kD subunit ("p35") and an approximately 40 kD subunit ("p40"), which was originally identified as a factor which induces γ -interferon from T cells and natural killer cells. as set forth in PCT/US91/06332, published April 2, 1992, which is incorporated herein by reference. PCT/US91/06332 refers to IL-12 as Natural Killer Cell Stimulating Factor or NKSF. EP 433827, published June 26, 1991 discloses IL-12 as a cytotoxic lymphocyte maturation factor (CLMF). These patent publications also disclose the cloning and expression of IL-12 and its subunits. Thus, through advances in recombinant DNA technology, it has been possible to produce IL-12 protein.

20

Interleukin-12 also stimulates natural killer cells *in vitro* by increasing their ability to lyse target cells at a level comparable to that obtained with interferon- α and interleukin-2, well-known activators of natural killer cells' cytotoxic activity. Additional *in vitro* activities of interleukin-12 which have been identified include induction of T cell proliferation as a co-stimulant; suppression of interleukin-2 induced proliferation of natural killer blasts; suppression of interleukin-2 induced proliferation of T cell receptor- $\gamma\delta$ -positive cells; promotion of Th1 T cell differentiation from progenitors; enhancement of Th1, but not Th2 proliferation; enhancement of T cell cytolytic activity; enhancement of cytotoxic lymphocyte generation; enhancement of natural killer and natural killer blast cytolytic activity; *ex vivo* enhancement of natural killer activity in peripheral blood mononuclear cells of interleukin-2-treated patients; induction of adhesion molecules on natural killer cells; induction of perforin and granzyme B mRNAs in natural killer blasts;

30

induction of interleukin-2 receptor subunits (p55, p75) on natural killer cells; induction of low levels of tumor necrosis factor- α ; suppression of IgE synthesis by interferon- γ -dependent and independent mechanisms; modulation of T cell development in fetal thymic organ cultures; and synergy with kit ligand to promote growth of myeloid and B cell progenitors. The known *in vivo* activities of interleukin-12 include induction of interferon- γ ; enhancement of natural killer cell activity in spleen, liver, lungs and peritoneal cavity; enhancement of generation of allo-specific cytotoxic lymphocytes; induction of extramedullary hematopoiesis in mouse spleen; reversible suppression of hematopoiesis in bone marrow; reversible induction of anemia, lymphopenia, and neutropenia in mice; suppression of anti-IgD induced IgE, IgG1, and interleukin-4 expression; increased survival in SCID mice treated with *Toxoplasma gondii*; cure of leishmaniasis in susceptible strains of mice; decreased bioburden in cryptococcoses model; suppression of tumor growth; and promotion of immunity to tumor cells. Interleukin-12 is also induced *in vivo* in the shwarzman reaction model of septic shock.

It is desirable to have concentrated forms of bulk protein, *e.g.*, IL-12, which, in turn, may be stored and which are suitable for further manufacture of finished dosage forms of protein. Typically, a purification process for a protein results in concentrating the protein. This concentrated protein, also known as bulk protein, may be in a formulation buffer. Bulk protein, typically at a concentration of about 0.1 to at least 20 mg/ml, can then be shipped frozen to a fill/finish facility where it is diluted to an appropriate dosage concentration and placed into dosage vials. These diluted samples can be lyophilized, *i.e.*, freeze-dried. The lyophilized samples may be kept in long-term storage and reconstituted at a later time by adding a suitable administration diluent just prior to patient use.

Protein stability can be affected *inter alia* by such factors as ionic strength, pH, temperature, repeated cycles of freeze/thaw and exposures to shear forces. Active protein may be lost as a result of physical instabilities, including denaturation and aggregation (both soluble and insoluble aggregate formation), as well as chemical instabilities, including, for example, hydrolysis, deamidation and

oxidation, to name just a few. For a general review of stability of protein pharmaceuticals, see, for example, Manning, *et al.*, *Pharmaceutical Research* 6:903-918 (1989).

While the possible occurrence of protein instabilities is widely appreciated, it is impossible to predict particular instability problems of a particular protein. Any of these instabilities can result in the formation of a protein, protein by-product, or derivative having lowered activity, increased toxicity, and/or increased immunogenicity. Also, IL-12 has a tendency to form soluble high molecular weight aggregates which can interfere with product quality and effectiveness in use. Thus, the safety and efficacy of any pharmaceutical formulation of a protein is dependent upon its stability.

In addition to stability considerations, one generally selects excipients which are or will meet with the approval of various world-wide medical regulatory agencies. The solution should be isotonic and the pH in a physiologically suitable range. The choice and amount of buffer used is important to achieve and maintain the desired pH range.

Ideally, formulations should also be stable for IL-12 bulk storage in high concentration (≥ 20 mg/ml, for example) which allows for relatively small volumes for fill/finish at the appropriate dose and also allows for alternate methods of administration which may require high protein concentration, *e.g.*, *sub cutaneous* administration. Accordingly, there continues to exist a need in the art for methods for monitoring IL-12 protein stability (and maintaining activity levels) during the concentration process and the lyophilization process, as well as providing stable formulations during prolonged storage.

25

BRIEF SUMMARY OF THE INVENTION

One aspect of the present invention provides novel compositions and methods for providing concentrated preparations of IL-12, useful as drug product. These compositions, either frozen, liquid, or lyophilized (preferably lyophilized), comprise: (a) a protein selected from the group consisting of IL-12, a biologically active fragment of IL-12, a subunit of IL-12, and a multimer of a subunit of IL-12; (b) a polysorbate; (c) a cryoprotectant; (d) a bulking agent; and (e) a buffering agent

which maintains the pH of said composition in the range of from about 4.5 to about 7.4.

Preferably, the cryoprotectant is selected from the group consisting of sucrose, maltose, lactose and combinations thereof. Preferably, the cryoprotectant
5 comprises about 0.5 to about 5% of the composition. When sucrose is used, a preferred concentration is from about 0.5 to about 2%, most preferably about 2%. Preferably the bulking agent is selected from the group consisting of mannitol, glycine and combinations thereof. Preferably the bulking agent comprises about 1 to about 5% of the composition. When mannitol is used, a preferred concentration
10 is from about 3 to 5%, most preferably about 4.15%. Combinations of sucrose/mannitol and sucrose/glycine are particularly preferred.

Preferably the polysorbate is selected from the group consisting of tween-20 and tween-80, most preferably tween-20. In certain embodiments, the polysorbate is present at a concentration of about 0.001 to 0.1%, preferably at a concentration
15 of about 0.001 to 0.1%, most preferably at a concentration of about 0.02%. A plurality of polysorbates may also be used.

In preferred embodiments, the buffering agent maintains the pH of said composition in the range of from about 5.2 to about 7.4, most preferably at about 5.6. Preferred buffering agents are selected from the group consisting of succinate,
20 histidine, phosphate, Tris, and diethanolamine, with succinate (particularly the sodium and potassium salts thereof) being most preferred.

Preferably the protein is present at a concentration of about 1 $\mu\text{g}/\text{ml}$ to about 20 mg/ml , more preferably at about 1 to about 1000 $\mu\text{g}/\text{ml}$, most preferably at a concentration of about 5 to about 500 $\mu\text{g}/\text{ml}$.

25 Particularly preferred embodiments of the invention comprise about 5 to about 500 $\mu\text{g}/\text{ml}$ IL-12, about 2% sucrose, about 4.15% mannitol, about 10 mM sodium succinate, and about 0.02% tween-20, and having a pH of about 5.6.

BRIEF DESCRIPTION OF THE FIGURES

30 Fig. 1 shows the results of SDS-PAGE analysis of rhIL-12 at a variety of pH's for 16 weeks at 30°C.

Fig. 2 shows quantitative SDS-PAGE data collected up to 12 weeks of storage at 30°C at various pHs.

Fig. 3 shows a Size Exclusion Chromatography (SEC) analysis of rhIL-12 at a variety of pHs after storage for 26 weeks at 30°C.

5 Fig. 4 shows the results of isoelectric focusing of rhIL-12 at a variety of pHs after storage for 16 weeks at 30°C.

Fig. 5 shows a plot of a fitted line representing the rate (k), which can be thought of as percent loss (rhIL-12 heterodimer) or gain (high molecular weight (HMW) aggregate) per week of storage.

10 Fig. 6 is a graph comparing the cake quality of rhIL-12 formulations containing different combinations of cryoprotectants and bulking agents.

Fig. 7 shows SEC traces from a 2x2 multi-variable matrix experiment and demonstrates that a tween-80 micelle co-elutes with the HMW aggregate.

15 Fig. 8 shows an overlay of SEC traces from formulations containing tween-20, with and without 0.1 mg/ml rhIL-12.

Fig. 9 shows the results of an adsorption study comparing tween-20 with tween-80.

Fig. 10 shows the results of a freeze/thaw study comparing tween-20 with tween-80.

20 Fig. 11 shows the results of a shaking study of various rhIL-12 formulations.

Figs. 12-14 are graphs showing the progression of rhIL-12 concentration over time for test formulations containing 0.1 mg/ml, 0.05 mg/ml and 0.01 mg/ml rhIL-12, respectively.

25 Figs. 15-17 are graphs showing the progression of HMW aggregate content over time test formulations containing 0.1 mg/ml, 0.05 mg/ml and 0.01 mg/ml rhIL-12, respectively.

DETAILED DESCRIPTION OF THE INVENTION

30 As used herein, the terms lyophilization, lyophilized, and freeze-dried include but are not limited to processes including "freezing" a solution followed by "drying", optionally *in vacuo* (although vacuum is not preferred). As used herein, the term "bulking agent" comprises agents which provide good lyophilized cake

properties, which help the protein overcome various stresses (shear/freezing for example) associated with the lyophilization process, and which help to maintain protein activity levels. Exemplary bulking agents include, but are not limited to, glycine, mannitol, MgCl_2 , CaCl_2 , NaCl , and the like. These agents contribute to the tonicity of the formulations. Cryoprotectants also contribute to the tonicity. The term "cryoprotectants" generally includes agents which provide stability to the protein from freezing-induced stresses; however, the term also includes agents that provide stability, *e.g.*, to bulk drug formulations during storage from non-freezing-induced stresses. Exemplary cryoprotectants include polyols, and include saccharides such as sucrose and mannitol, as well as including surfactants such as polysorbate, or polyethyleneglycol, and the like. The term "cryoprotectant" includes agents that provide stability to the protein during water removal from the system during the drying process, presumably by maintaining the proper conformation of the protein through hydrogen bonding. Cryoprotectants can also have lyoprotectant effects; therefore, the terms "cryoprotectant" and "lyoprotectant" are used interchangeably herein.

The term "buffering agent" encompasses those agents which maintain the solution pH in an acceptable range prior to lyophilization and may include succinate (sodium or phosphate), histidine, phosphate (sodium or potassium), Tris (tris (hydroxymethyl) aminomethane), diethanolamine, and the like. The upper concentration limits are generally higher for "bulk" protein than for "dosage" protein forms as is readily appreciated by one skilled in the art. For example, while buffer concentrations can range from several millimolar up to the upper limit of their solubility, *e.g.*, succinate could be as high as 200 mM, one skilled in the art would also take into consideration achieving/maintaining an appropriate physiologically suitable concentration. Percentages are weight/weight when referring to solids and weight/volume when referring to liquids. The term "isotonic," 300 ± 50 mOsM, is meant to be a measure of osmolality of the protein solution prior to lyophilization; reconstitution is typically with water for injection (WFI). Maintaining physiological osmolality is important for the dosage formulations. However, for bulk formulations, much higher concentrations can be effectively utilized as long as the solution is made isotonic prior to use. The term

"excipients" includes pharmaceutically acceptable reagents to provide good lyophilized cake properties (bulking agents) as well as provide lyoprotection and cryoprotection of the protein, maintenance of pH, and proper conformation of the protein during storage so that substantial retention of biological activity (protein stability) is maintained. Preferably, the combined concentration of the excipients provides a combined osmolality of about 250 to about 350 milliosmol (mOsm) per kg, more preferably about 300 mOsm/kg.

In accordance with the present invention, therefore, native IL-12 is a heterodimeric glycoprotein comprised of two covalently linked subunits, one of said subunits having a molecular weight of about 40 kD, and the other subunit having a molecular weight of about 35 kD. Any form of IL-12 may be used to practice the invention. For example, IL-12 may be in the form of the heterodimer comprised of a 40 kD subunit disulfide-bonded to a 35 kD subunit. When IL-12 is a heterodimer, the 40 kD subunit has substantial homology to the 40 kD subunit of human IL-12 as set forth in PCT/US91/06332 or EP 433827 and is disulfide bonded to a 35 kD subunit having substantial homology to the 35 kD subunit of human IL-12 as set forth in those patent publications. "Substantial homology" means greater than 75% homology at the amino acid level, while retaining the desired biological function. Another form of IL-12 which may be used in the present invention is an IL-12 subunit. Such an IL-12 40 kD subunit has substantial homology to the human IL-12 40 kD subunit, and such an IL-12 35 kD subunit has substantial homology to the human IL-12 35 kD subunit. Fragments of the IL-12 subunits that retain IL-12 biological activity are also be useful for making formulations in accordance with the present invention. Multimers, such as homodimers, of IL-12 subunits may also be used.

For use in the present invention, it is preferable to produce IL-12 recombinantly, through expression of DNA sequences encoding one or both of the IL-12 subunits in a suitable transformed host cell. For example, using known methods the DNA sequences encoding human IL-12 may be linked to an expression vector such as pED (Kaufman et al., Nucleic Acids Res. 19, 4484-4490(1991)). In such an expression vector, sequences which optimize translation such as CCACC (Kozak, M., Nucleic Acids Res. 12, 857-871 (1984)) may be added 5' to the

initiation codon using known methods. The expression vector containing the IL-12 subunits may then be transformed into a host cell, and protein expression may be induced and maximized, to produce heterodimeric human IL-12. For production of heterodimeric IL-12, the DNA sequences encoding the IL-12 subunits may be present on different expression plasmids or present in tandem on a single expression plasmid.

When a subunit or fragment of IL-12 is used to practice the present invention, it may also be produced recombinantly using known methods. For example, the DNA sequence encoding the human IL-12 40 kD subunit may be linked to an expression vector, transformed into a host cell, and expression induced and maximized to produce the human IL-12 40 kD subunit. Similarly, the DNA sequences encoding the human IL-12 35 kD subunit may be linked to an expression vector, transformed into a host cell, and expression induced and maximized to produce the corresponding protein. Of course, degenerate DNA sequences encoding the IL-12 subunits may also be employed to produce IL-12 for use in the present invention, as can DNA sequences encoding allelic variants of the IL-12 subunits.

Any suitable expression vector may be employed to produce IL-12 for use in the present invention. For mammalian expression, numerous expression vectors are known in addition to the pED vector mentioned above, such as pEF-BOS (Mizushima et al., *Nucleic Acids Res.* 18, 5322 (1990)); pXM, pJL3 and pJL4 (Gough et al., *EMBO J.* 4, 645-653 (1985)); and pMT2 (derived from pMT2-VWF, A.T.C.C. #67122; see PCT/US87/00033). Suitable expression vectors for use in yeast, insect, and bacterial cells are also known. Construction and use of such expression vectors is well within the level of skill in the art.

Suitable host cells for recombinant production of IL-12 useful in the present invention include, for example, mammalian cells such as Chinese hamster ovary (CHO) cells, monkey COS cells, mouse 3T3 cells, mouse L cells, myeloma cells such as NSO (Galfre and Milstein, *Methods in Enzymology* 73, 3-46 (1981)), baby hamster kidney cells, and the like. IL-12 may also be produced by transformation of yeast, insect, and bacterial cells with DNA sequences encoding the IL-12 subunits, induction and amplification of protein expression, using known methods.

Recombinantly produced IL-12 can be purified from culture medium or cell extracts by conventional purification techniques. Culture medium or cell extracts containing IL-12 may be concentrated using a commercially available protein concentration filter, for example, an Amicon or Millipore Pellicon ultrafiltration unit. Following the concentration step, the concentrate can be applied to a purification matrix such as a gel filtration medium. Alternatively, an anion exchange resin can be employed, for example, a matrix or substrate having pendant diethylaminoethyl (DEAE) groups. The matrices can be acrylamide, agarose, dextran, cellulose or other types commonly employed in protein purification. Alternatively, a cation exchange step can be employed. Suitable cation exchangers include various insoluble matrices comprising sulfopropyl or carboxymethyl groups.

The purification of IL-12 from culture supernatant may also include one or more column steps over such affinity resins as lectin-agarose, heparin-toyopearl® or Cibacrom blue 3GA Sepharose®; or by hydrophobic interaction chromatography using such resins as phenyl ether, butyl ether, or propyl ether; or by immunoaffinity chromatography. Finally, one or more reverse-phase high performance liquid chromatography (RP-HPLC) steps employing hydrophobic RP-HPLC media, e.g., silica gel having pendant methyl or other aliphatic groups, can be employed to further purify IL-12 for use in the present methods and compositions. Some or all of the foregoing purification steps, in various combinations, can be employed to provide a substantially homogeneous isolated recombinant protein. Purification of IL-12 subunits or fragments for use in the present invention may differ from the optimal protocol for purification of the heterodimeric protein.

Preferably, when human IL-12 is produced recombinantly as set forth above, it may be purified by the following method. The cells in which the human IL-12 has been made may be removed from the conditioned medium by filtration, and the conditioned medium is loaded onto Q-Sepharose FastFlow™ (available from Pharmacia) or an equivalent anion exchange medium, which has been equilibrated in 10-30 mM Tris-HCl, pH 7.8-8.3. The column is then washed extensively with the same buffer followed by a wash with 30-45 mM histidine, pH 5.1-5.8, followed by a wash with the original equilibration buffer. The recombinant human IL-12 is eluted from the column with a buffer containing 20-50 mM Tris-HCl, pH 7.8-8.5.

and 0.15 to 0.50 M NaCl. the eluted material is loaded onto CM-Sepharose FastFlow™ (available from Pharmacia) or equivalent cation exchange medium which has been equilibrated in 20-50 mM MES, pH 5.7-6.4, and washed extensively with the same buffer. The column is washed with a buffer containing 20-40 mM sodium phosphate, pH 6.8-7.5 and 0.2-0.5 M NaCl. The eluted material is concentrated using an Amicon™ S1Y30 or equivalent spiral cartridge membrane which has been washed and equilibrated in the elution buffer used in the CM-Sepharose FastFlow™ column. The material is concentrated to approximately 5% of the column volume of the final chromatographic step, which is further purified via size exclusion using S200 Sephacryl™ (available from Pharmacia) or an equivalent size exclusion resin. The size exclusion column is equilibrated and eluted with phosphate buffered saline, pH 7.2-7.6, and the recombinant human IL-12 peak is collected and filtered for use in the method of the invention. Those of skill in the art of protein purification may use alternative purification methods to obtain recombinantly-produced human IL-12 for use in the method of the invention.

IL-12 may be purified from culture medium or extracts of cells which naturally produce the protein and used in the present invention. Exemplary purification schemes for naturally produced IL-12 are set forth in PCT/US91/06332 and in EP 433827.

The following examples illustrate practice of the invention. These examples are for illustrative purposes only and are not intended in any way to limit the scope of the invention claimed.

Example 1

Examination of Effect of pH

The effects of pH on the stability and solubility of recombinant human IL-12 (rhIL-12) was examined in a six month stability study. rhIL-12 at a concentration of 1.2 mg/ml was dialyzed into seven buffer ranging in pH from 3.5 to 9.6 (pH 3.5, NaCitrate; pH 4.5, NaGlutamate; pH 5.5, NaSuccinate; pH 6.5, Histidine; pH 7.2, NaPhosphate; pH 8.3, Tris; pH 9.6, glycine). Samples were aseptically vialled and then stored at -80°C, 4°C, 30°C, 40°C and 50°C. Samples were periodically

removed from storage to be analyzed by SEC-HPLC, SDS-PAGE, IEF and RP-HPLC.

Fig. 1 shows the results of SDS-PAGE analysis of rhIL-12 at a variety of pH's for 16 weeks at 30°C. An ISS 3-27% Sepragel was run at constant current with Laemli buffer using a 4.5% acrylamide stack. The gel was silver stained using a Daiichi Silver Stain II kit.

Fig. 2 shows quantitative SDS-PAGE data collected up to 12 weeks of storage at 30°C at various pHs. Gels were coomassie stained and scanned using a Pharmacia LKB gel scanner. This provided a means to correlate the gels with Size Exclusion Chromatography.

Fig. 3 shows a Size Exclusion Chromatography (SEC) analysis of rhIL-12 at a variety of pHs after storage for 26 weeks at 30°C. A Tosohaas 7.6x300mm TSK3000swxl column was run isocratically at 0.9 ml/min for 18 minutes using a 20mM NaH_2PO_4 , 350mM NaCl, pH 7.0 running buffer and a 10 μg load. The method was run on a Hewlett Packard 1090 HPLC.

Fig. 4 shows the results of isoelectric focusing of rhIL-12 at a variety of pHs after storage for 16 weeks at 30°C. A Pharmacia PAGplate (pI 4.0 to pI 6.5) was prefocused at 1000V, 15 mA, 15W with 0.5M acetic acid (anode) and 0.5M NaOH (cathode). 5 μg of each sample was loaded using a sample applicator strip. The gel was run at 1000V, 15 mA, 15W for 2.5 hours, fixed in 20% TCA in EtOH for 45 minutes and then silver stained using the Daiichi Silver Stain II kit.

Fig. 5 shows a plot of the rates of generation of various degradation products as a function of pH. This data is based on Figs. 1-4. The data is summarized in Table I below:

Table I

| Instability | Preferable pH Range |
|----------------------------------|---------------------|
| aggregation via SEC-HPLC | pH 4.5 - 5.5 |
| aggregation via SDS-PAGE | pH 4.5 - 5.5 |
| 5 generation of p40 subunit | pH 5.5 - 8.3 |
| generation of clips via SDS-PAGE | pH \geq 5.5 |
| charge changes via IEF* | pH 4.5 - 6.5 |
| generation of 50kD species | pH \geq 5.5 |

10 * not included in Fig 5; data presented in Fig. 4.

Focusing on the 30°C data set, a number of conclusions can be drawn: (1) Aggregation is minimized at pH 4.5 to 5.5 as observed both by SEC-HPLC and SDS-PAGE analysis. (2) Dissociation of the heterodimer is demonstrated by
 15 increased levels of p40 subunit as shown by reversed-phase HPLC and SDS-PAGE; this is minimized at pH 5.5 - 8.3. (3) Generation of clipped forms is minimized at pH \geq 5.5 as shown by RP-HPLC and SDS-PAGE, thus avoiding acid-catalyzed hydrolysis. (4) Generation of a 50 kD species is minimized at pH \geq 5.5. (5) Charge changes observed by IEF gel analysis shows the most stability at pH 4.5 -
 20 5.5. At basic pH, the samples migrate toward the anode, potentially indicative of deamidation. Based on these results, the most stable pH is approximately 5.5.

Example 2

Examination of Effect of Cryoprotectants and Bulking Agents

25 Several cryoprotectant and bulking excipients were examined for their freeze drying properties. Cryoprotectants examined included glucose, sucrose, maltose, trehalose, fructose and lactose. Bulking agents examined included glycine, mannitol and sorbitol. After differential scanning calorimetry studies (data not shown) six combinations of a cryoprotectant and a bulking agent were selected for further
 30 study: sucrose/mannitol, maltose/mannitol, lactose/mannitol, sucrose/glycine, maltose/glycine and glucose/glycine.

The six combinations of excipients were combined in nine ratios and freeze-dried using a gentle lyophilization cycle. Each sample contained 0.5 mg/ml rhIL-12 and 10mM succinate, pH 5.6 (1 ml fill in a 5 ml vial). Cake quality was judged from 1 (worst) to 5 (best). The results are shown in Fig. 6.

- 5 The freeze-dried vials prepared as described above were reconstituted and examined for the level of HMW aggregate. In addition, osmolalities were calculated for each of the combinations. The data are reported in Table II.

Table II

Top value = cake quality (5 is best, 1 is worst)

Middle value = calculated osmolality (mOsm/kg)

5 Bottom value = percent HMW aggregate after lyophilization and reconstitution

| | | Ratio of Lyoprotectant to Bulking Agent | | | | | | | | |
|-------------------|----------------------|---|------------------|------------------|------------------|------------------|------------------|------------------|------------------|----------------------|
| excipient pairing | | .5/3 | .5/2 | 1/3 | .5/1 | 1/2 | 2/3 | 1/1 | 2/2 | 2/1 |
| 10 | sucrose/ glycine | 5 522 0.76 | 5 354 0.70 | 5 537 0.89 | 4 185 0.68 | 5 369 0.95 | 5 567 0.95 | 1 200 1.02 | 1 399 1.03 | 1 230 0.9 4 |
| | | 4 522 0.79 | 5 354 0.66 | 4 537 0.88 | 3 185 0.45 | 5 369 0.69 | 4 567 0.67 | 1 200 0.65 | 1 399 0.52 | 1 230 0.5 5 |
| 15 | glucose/ glycine | 5 532 1.12 | 5 364 1.05 | 5 564 0.74 | 2 195 0.86 | 5 396 0.73 | 4 622 0.65 | 1 227 0.63 | 1 454 0.78 | 1 285 0.7 7 |
| | | 5 185 2.19 | 5 127 1.91 | 5 200 1.47 | 1 127 2.42 | 5 142 1.26 | 5 230 1.31 | 2 85 1.66 | 3 172 1.73 | 2 115 1.5 3 |
| 20 | maltose/ mannitol | 5 185 1.77 | 5 127 1.96 | 5 200 1.91 | 2 127 1.33 | 5 142 2.10 | 5 230 1.58 | 1 85 2.02 | 2 172 1.73 | 2 115 1.6 3 |
| | | 5 185 2.20 | 5 127 2.45 | 5 200 2.00 | 1 127 2.66 | 5 142 2.22 | 5 230 1.55 | 2 85 2.18 | 3 172 1.67 | 2 115 1.3 7 |

These data indicated twelve combinations (shaded boxes) which were chosen for further study based on cake quality, osmolality (300 mOsm/kg is isotonic), and HMW aggregate levels.

The twelve chosen formulations from Table II were optimized to be isotonic, and then were freeze-dried. All formulations contained 0.1 mg/ml rhIL-12, 0.02%

tween-80, 10mM sodium succinate, pH 5.6. Residual moisture, percent HMW aggregate (post-lyophilization) and cake quality (1=poor, 3=excellent) were measured. Osmolality was calculated. The results are reported in Table III.

5

Table III

| Formulation | Residual Moisture | % HMW (post-lyo) | Cake Quality | Osmolal. mOsm/kg |
|-------------------------------|-------------------|------------------|--------------|------------------|
| 0.5% sucrose 1.63% glycine | 0.12 | 7.15 | 2 | 293 |
| 1% sucrose 1.63% glycine | 0.90 | 6.00 | 1 | 307 |
| 0.5% maltose 1.63% glycine | 0.14 | 7.91 | 2 | 293 |
| 1% maltose 1.63% glycine | 1.90 | 7.35 | 1 | 307 |
| 0.5% glucose 1.63% glycine | -0.19 | 6.06 | 2 | 302 |
| 1% glucose 1.63% glycine | 1.34 | 6.57 | 1 | 300 |
| 1% sucrose 4.67% mannitol | 0.41 | 12.53 | 3 | 300 |
| 2% sucrose 4.15% mannitol | 0.56 | 9.88 | 3 | 300 |
| 1% maltose 4.67% mannitol | 0.42 | 11.71 | 3 | 300 |
| 2% maltose 4.15% mannitol | 0.50 | 8.90 | 3 | 300 |
| 1% lactose 4.67% mannitol | 0.44 | 7.52 | 3 | 300 |
| 2% lactose 4.15% mannitol | 0.64 | 11.40 | 3 | 300 |

Residual moisture analysis of the cakes indicated that the combinations provided sufficient dryness (<1%). Cake quality was generally good, but HMW aggregate levels were elevated. Optimization of the lyophilization cycle used in the generation

of these samples could result in increased cake quality. Based on these data five candidates (shaded) were selected for further examination.

Example 3

5

Examination of Effects of Polysorbate

Experiments determined that tween-80 helped to prevent precipitation of rhIL-12 during freeze/thaw cycles and shaking, as well as preventing adsorption of rhIL-12 to glass surfaces. Adsorption of a lyophilized dosage form after reconstitution is a distinct possibility due to the fact that rhIL-12 will likely be formulated at a very low protein concentration (10-100 $\mu\text{g/ml}$). To alleviate this potential problem, tween-80 was added to formulation candidates at a concentration of 0.02%. At this concentration, tween-80 provided the desired results.

However, at this particular concentration tween-80 also forms micelles that co-elute with HMW aggregate when resolved by SEC. Fig. 7 shows SEC traces from a 2x2 multi-variable matrix experiment and demonstrates that a tween-80 micelle co-elutes with the HMW aggregate. This artificially inflates the HMW species values at low protein concentrations, making the assay less accurate. Switching to tween-20 corrected this problem. Fig. 8 shows an overlay of SEC traces from formulations containing tween-20, with and without 0.1 mg/ml rhIL-12. This figure demonstrates that the tween-20 micelle does not co-elute with the HMW aggregate. However, it was necessary to establish that tween-20 performed as well as tween-80 with respect to handling and adsorption.

Fig. 9 shows the results of an adsorption study comparing tween-20 with tween-80. rhIL-12 at 2 and 5 $\mu\text{g/ml}$ containing either tween-20 or tween-80 at .001% or .01% in 10 mM sodium succinate pH 5.6 was allowed to stand at room temperature in a 5 ml glass vial for 0, 3 and 7 days. Samples were analyzed by fluorescence spectroscopy ($\text{ex}=295 \text{ nm}$, $\text{em}=337$) and compared to a standard curve (2 to 10 $\mu\text{g/ml}$ also by fluorescence). Recoveries are based on day 0 data. These data demonstrate that tween-20 is as good as, if not better than, tween-80.

Fig. 10 shows the results of a freeze/thaw study comparing tween-20 with tween-80. rhIL-12 at 20 $\mu\text{g/ml}$ containing either tween-20 or tween-80 at .001% or .01% in 10 mM sodium succinate pH 5.6 were taken through 10 freeze/thaw cycles.

Aliquots were taken at cycles 0, 2, 4, 6, 8 and 10 and were analyzed by fluorescence as described above for Fig. 9. Recoveries are based on the 0 cycle data. These data demonstrate that tween-20 performs as well as tween-80 in providing some cryoprotectant effects. Addition of either tween-20 or tween-80 was better than addition of no polysorbate.

Fig. 11 shows the results of a shaking study. rhIL-12 at 0.1 mg/ml in a variety of candidate formulations at seven different concentrations of tween-20 were shaken vigorously for 72 hours. The samples were filtered and assayed by reverse phase chromatography. Recovery is total protein based on samples that were not shaken.

Example 4

Stability Studies

The stability of several formulations was studied over time. A sucrose/glycine formulation ("SG" or "SucGly") was used which contained 0.5% sucrose, 1.63% glycine, .01% tween-20, 10 mM sodium succinate, pH 5.6. A sucrose/mannitol formulation ("SM" or "SucMan") was used which contained 2.0% sucrose, 4.15% mannitol, .02% tween-20, 10 mM sodium succinate, pH 5.6. Both of these formulations were used to make test formulations containing three different protein concentrations (0.1 mg/ml, 0.05 mg/ml and 0.01 mg/ml rhIL-12). The various test formulations were stored at 4°C, 30°C and 40°C. Samples were assayed for rhIL-12 concentration and HMW aggregate content at various time intervals.

Figs. 12-14 show the progression of rhIL-12 concentration over time for the 0.1 mg/ml, 0.05 mg/ml and 0.01 mg/ml rhIL-12 test formulations, respectively. Figs. 15-17 show the progression of HMW aggregate content over time for the 0.1 mg/ml, 0.05 mg/ml and 0.01 mg/ml rhIL-12 test formulations, respectively.

While the present invention has been described in terms of specific methods, formulations, and compositions, it is understood that variations and modifications will occur to those skilled in the art upon consideration of the present invention.

- Numerous modifications and variations in the invention as described in the above illustrative examples are expected to occur to those skilled in the art and, consequently, only such limitations as appear in the appended claims should be placed thereon. Accordingly, it is intended in the appended claims to cover all such equivalent variations which come within the scope of the invention as claimed.
- 5

WHAT IS CLAIMED IS:

1. A composition comprising: (a) a protein selected from the group consisting of IL-12, a biologically active fragment of IL-12, a subunit of IL-12, and a multimer of a subunit of IL-12; (b) a polysorbate; (c) a cryoprotectant; (d) a bulking agent; and (e) a buffering agent which maintains the pH of said composition in the range of from about 4.5 to about 7.4.
2. The composition of claim 1, wherein said cryoprotectant is selected from the group consisting of sucrose, maltose, lactose and combinations thereof.
3. The composition of claim 2, wherein said cryoprotectant is sucrose.
4. The composition of claim 3, wherein the concentration of sucrose in said composition is about 0.5 to 2%.
5. The composition of claim 4, wherein said sucrose concentration is about 2%.
6. The composition of claim 1, wherein said bulking agent is selected from the group consisting of mannitol, glycine and combinations thereof.
7. The composition of claim 6, wherein said bulking agent is mannitol.
8. The composition of claim 7, wherein the concentration of mannitol in said composition is about 3 to about 5%.
9. The composition of claim 8, wherein said concentration is about 4.15%.
10. The composition of claim 1, wherein said polysorbate is selected from the group consisting of tween-20 and tween-80.
11. The composition of claim 10, wherein said polysorbate is tween-20.

12. The composition of claim 11, wherein said polysorbate is present at a concentration of about 0.001 to 0.1%.
13. The composition of claim 12, wherein said polysorbate is present at a concentration of about 0.02%.
14. The composition of claim 1, wherein said buffering agent maintains the pH of said composition in the range of from about 5.2 to about 7.4.
15. The composition of claim 14, wherein said buffering agent maintains the pH of said composition at about 5.6.
16. The composition of claim 1, wherein said buffering agent is selected from the group consisting of succinate, histidine, phosphate, Tris, and diethanolamine.
17. The composition of claim 15, wherein said buffering agent is sodium succinate.
18. The composition of claim 15, wherein said buffering agent is potassium succinate.
19. The composition of claim 1, wherein said protein is IL-12.
20. The composition of claim 1, wherein said protein is present at a concentration of about 1 to about 1000 $\mu\text{g/ml}$.
21. The composition of claim 20, wherein said protein is present at a concentration of about 5 to about 500 $\mu\text{g/ml}$.
22. The composition of claim 1, comprising about 5 to about 500 $\mu\text{g/ml}$ IL-12, about 2% sucrose, about 4.15% mannitol, about 10 mM sodium succinate, and about 0.02% tween-20, and having a pH of about 5.6.

23. The composition of claim 1, wherein said composition is lyophilized.




Figure 1





Figure 2





Figure 3



1. pH 3.5
2. pH 4.5
3. pH 5.5
4. pH 6.5
5. pH 7.2
6. pH 8.3
7. pH 9.6
8. 2853-94 ref.std.
9. pl marker

Figure 4

RATE AS A FUNCTION OF pH FOR A VARIETY OF rhIL-12 DEGRADATION PRODUCTS




Figure 5




Figure 6




Figure 7.




Figure 8

50




Figure 9.

Freeze/Thaw: Comparison of Tween-20 and Tween-80




Figure 10

% Recovery of rhIL-12 after Shaking for 72 Hours
as a Function of Tween-20 Concentration






Figure 11

12-A



12-B



12-C






Fig. 12

12/17

13-A



13-B



13-C






Fig. 13

14-A



14-B



14-C






Fig. 14

14/17

15-A



15-B



15-C




Fig. 15

15/17






Fig. 16

17-A



17-B



17-C




Fig. 17

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 96/01382

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K38/20 A61K47/00 A61K47/26

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|---|-----------------------|
| A | DE,A,43 15 127 (BEHRINGWERKE AG,DE) 10 November 1994 see claims see column 4, line 5 - line 11 --- | 1-23 |
| A | EP,A,0 433 827 (F. HOFFMANN-LA ROCHE AG,CH) 26 June 1991 cited in the application see claims 1,28-30 see page 9, line 5 - line 16 --- | 1-23 |
| A | WO,A,92 05256 (GENETICS INSTITUTE INC.,U.S.A.) 2 April 1992 cited in the application see claims 1,16-18 see page 34, line 16 - page 35, line 7 --- -/-- | 1-23 |

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

6 June 1996

Date of mailing of the international search report

14.06.1996

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Scarponi, U

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 96/01382

| C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT | | |
|--|--|-----------------------|
| Category | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
| A | WO,A,90 05147 (GENETICS INSTITUTE INC.,U.S.A.) 17 May 1990 see claims 1,21-23 see page 25, line 12 - page 26, line 4 --- | 1-23 |
| A,P | EP,A,0 640 689 (F. HOFFMANN-LA ROCHE AG,CH) 1 March 1995 see claims 1,6-11 see page 5, line 14 - line 47 --- | 1-23 |
| A,P | WO,A,95 19786 (GENETICS INSTITUTE INC.,U.S.A.) 27 July 1995 see claims see page 14, line 17 - page 16, line 5 ----- | 1-23 |

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. Application No

PCT/US 96/01382

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date |
|---|---------------------|---|--|
| DE-A-4315127 | 10-11-94 | AU-B- 6190194 CA-A- 2123049 EP-A- 0625354 JP-A- 6329549 | 10-11-94 08-11-94 23-11-94 29-11-94 |
| EP-A-433827 | 26-06-91 | AU-B- 5471294 AU-B- 6834990 CA-A- 2032653 JP-A- 5294999 | 09-06-94 27-06-91 23-06-91 09-11-93 |
| WO-A-9205256 | 02-04-92 | US-A- 5457038 AU-B- 8723691 EP-A- 0549711 JP-T- 6501009 | 10-10-95 15-04-92 07-07-93 27-01-94 |
| WO-A-9005147 | 17-05-90 | AU-B- 638430 AU-B- 4667389 CA-A- 2002607 EP-A- 0441900 JP-T- 4502151 US-A- 5457038 | 01-07-93 28-05-90 10-05-90 21-08-91 16-04-92 10-10-95 |
| EP-A-640689 | 01-03-95 | AU-B- 6607294 CA-A- 2125763 JP-A- 7053594 NZ-A- 260843 | 12-01-95 03-01-95 28-02-95 27-02-96 |
| WO-A-9519786 | 27-07-95 | AU-B- 1687595 | 08-08-95 |

THIS PAGE BLANK (USPTO)